Patent ID: 8968730
Filing Date: 2015-03-03
Classification: A61K,A61P,C07K

Abstract:
1. A method of enhancing immune response to an antigen in a patient by blocking negative regulation of immune-complex-triggered activation, wherein said antigen is associated with a cancer or a neoplastic disease or is an antigen of a pathogen, said method comprising administering to said patient: (i) an antigen-antibody complex; and (ii) an antibody or an antigen-binding fragment thereof that specifically binds the extracellular domain of human FcγRIIB with greater affinity than human FcγRIIA and inhibits binding to the Fc binding site of human FcγRIIB, wherein said antibody or antigen-binding fragment thereof comprises the six CDRs of antibody produced by clone 2B6 having ATCC Accession No. PTA-4591 or the six CDRs of antibody produced by clone 3H7 having ATCC Accession No. PTA-4592; to thereby enhance immune response in said patient to said antigen.